Try our Advanced Search for more refined results
Amgen Inc. v. Apotex Inc.
Case Number:
17-1010
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
November 13, 2017
Fed. Circ. Clears Apotex In Neulasta Biosimilar Patent Row
A Federal Circuit panel upheld a lower court ruling that found Apotex Inc. did not infringe a patent covering Amgen Inc.'s blockbuster drug Neulasta, while clarifying the amount of weight courts should put on statements made in the prelitigation process by companies making biosimilars.
-
October 03, 2017
Fed. Circ. Looks At Early Statements In Neulasta Patent Row
Federal Circuit judges on Tuesday questioned how much weight courts should put on statements made in the prelitigation process by companies making copycat versions of biologic drugs, as Amgen looks to overturn a ruling that cleared Apotex of infringing a patent related to its blockbuster biologic Neulasta.